A peptide-based neoantigen vaccine for patients with advanced pancreatic cancer refractory to standard treatment.

e14563 Background: Tumor-specific neoantigens are considered as personalized and potential ultimate targets for cancer immunotherapy. Recently, neoantigen vaccines have been designed to train the patient's immune system specifically target kill tumor cells. However, safety efficacy of in pancreatic treatment remain poorly understood. Methods: Personalized peptide were successfully manufactured cancers with low mutation burden. Seven patients advanced refractory standard treatments enrolled treated vaccine, iNeo-Vac-P01. Besides evaluation clinical iNeo-Vac- P01, pre- post-vaccination peripheral blood samples collected analyze vaccine’s immunogenicity. Results: For all 7 patients, none sever vaccine-related adverse effects was witnessed. The mean progression free survival, overall survival (OS) OS associated vaccine 3.1, 24.1 8.3 months, respectively. Patient who had a 21-month treatment, abundance TCR clone remarkably increased after vaccination, indicating iNeo-Vac-P01 induce subset T cells This study also demonstrated that quantity IFN-γ might be biomarker OS. Conclusions: We believed it first tentative focused application peptide-based cancer. Promisingly, provide new strategy improve limited Clinical trial information: NCT03645148.